Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"LUMICKS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LUMICKS Enters Collaboration with Glycostem to Enhance NK cell-Mediated Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glycostem Initiates Phase I\/IIa (Pivotal) Trial to Evaluate the Safety and Efficacy of oNKord\u00ae in Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glycostem Announces New Data Presentation at EHA 2022 Congress Highlighting Early Safety and Clinical Course of oNKord\u00ae in Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Medac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glycostem and Medac Enter Into License, Manufacturing, Supply and Commercialization Agreement for Glycostem's Lead Product - oNKord","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Glycostem Therapeutics

    Menu

    Glycostem Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Glycostem Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Glycostem and Medac Enter Into License, Manufacturing, Supply and Commercialization Agreement for Glycostem's Lead Product - oNKord

              Details:

              Under the terms of the agreement, medac receives an exclusive license to commercialize oNKord® (GTA002) in the EU, the UK and further European countries for acute myeloid leukemia (AML) and multiple myeloma (MM) patients.

              Lead Product(s): GTA002,Cyclophosphamide,Fludarabine Phosphate

              Therapeutic Area: Oncology Product Name: oNKord

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Medac

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Glycostem Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Glycostem Announces New Data Presentation at EHA 2022 Congress Highlighting Early Safety and Clinical Course of oNKord® in Patients with Acute Myeloid Leukemia

              Details:

              oNKord (allogeneic ex vivo-generated NK cells) is immunotherapy product in clinical development. It gets produced in a closed system in Glycostem’s state-of-the-art and GMP licensed production facility, from which it can be distributed globally.

              Lead Product(s): Allogeneic Ex-vivo Generated NK cells,Cyclophosphamide,Fludarabine Phosphate

              Therapeutic Area: Oncology Product Name: oNKord

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Glycostem Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Glycostem Initiates Phase I/IIa (Pivotal) Trial to Evaluate the Safety and Efficacy of oNKord® in Patients with Acute Myeloid Leukemia

              Details:

              WiNK is a two-stage phase I/IIa trial to study the safety and efficacy of oNKord®, an off-the-shelf, ex. vivo-cultured allogeneic NK cell preparation, AML patients who are in complete morphologic remission with no strong indication for hematopoietic stem cell transplantation.

              Lead Product(s): oNKord

              Therapeutic Area: Oncology Product Name: oNKord

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 20, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Glycostem Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              FDA Grants Glycostem’s oNKord® Orphan Drug Designation for Multiple Myeloma

              Details:

              ONKord® is Glycostem’s first-generation off-the-shelf Natural Killer (NK) cellular immunotherapy product. Over the coming months, AML patients will receive this form of treatment as part of a phase I-IIa (pivotal) trial in AML.

              Lead Product(s): oNKord

              Therapeutic Area: Oncology Product Name: oNKord

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 12, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Glycostem Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LUMICKS Enters Collaboration with Glycostem to Enhance NK cell-Mediated Immunotherapy

              Details:

              Glycostem will assess their NK cells using LUMICKS’ z-Movi to gain new insights into the cell avidity and functional properties of their cells. Avidity is a new parameter that is crucial to understand immune cells better and choose the most potent ones for immunotherapy.

              Lead Product(s): CAR-NK cells

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: LUMICKS

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY